IONS - IONIS PHARMACEUTICALS INC

74.87
-0.840   -1.122%

Share volume: 1,051,311
Last Updated: 04-20-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$75.71
-0.84
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
38%
Profitability 16%
Dept financing 47%
Liquidity 75%
Performance 48%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.52%
1 Month
5.76%
3 Months
-5.75%
6 Months
4.51%
1 Year
162.61%
2 Year
82.30%
Key data
Stock price
$74.87
P/E Ratio 
0.00
DAY RANGE
$74.58 - $75.62
EPS 
-$2.38
52 WEEK RANGE
$28.79 - $86.74
52 WEEK CHANGE
$157.91
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-31-2025
BETA 
0.45
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,529,863
AVERAGE 30 VOLUME 
$1,800,573
Company detail
CEO: Brett P. Monia
Region: US
Website: ionispharma.com
Employees: 800
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.

Recent news